(Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the ...

The pair will work together to progress lixudebart across multiple rare kidney and liver diseases.

This is a real growth story, and FILSPARI is now the only approved medicine in its younger indication. But I rate the shares a Hold at this price. The valuation has run ahead of the evidence: roughly ...

Accordingto Bank of America Securities' initial coverage report, AP301's revenue in the Chinese market could reach ...

Today, the American Kidney Fund (AKF) is convening its seventh annual national summit on Unknown Causes of Kidney Disease (UCKD) in Washington, D.C., bringing healthcare professionals, researchers, ...

Travere Therapeutics (Nasdaq: TVTX) plans to present nine data sets, including five oral presentations, on its drug Filspari (sparsentan) at the American Society of Nephrology Kidney Week 2026 in ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alpha Cognition Inc (ACOG) and Travere Therapeutics (TVTX) with bullish sentiments. According to TipRanks ...

Today, the American Kidney Fund (AKF) and the IgA Nephropathy Foundation are on Capitol Hill with more than 80 advocates who are living with rare kidney diseases to urge elected officials to support ...

Summary:The company released its 2026 interim report, reporting revenue of RMB 1.148 billion for the first half of 2026, up ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...